The Perfect Storm: Viral Mimicry Meets Cancer Dark Matter

Joyce Hu; Francesco M. Marincola; Edward Clay; Erik Hett

Abstract

The central mechanism for immune recognition of cancer remains a subject of debate. Some theories emphasize the importance of cancer antigen specificity and immunogenicity while others focus on innate chemo attractive and immune-modulatory properties of cancer cells. The immune system evolved under strong selection to protect individuals during their reproductive years from infectious epidemics, which helped to preserve species. Since common cancers often occur after the reproductive stage of life, there is less evolutionary pressure to eliminate them as they do not pose a direct threat to the survival of the species. So, why does the immune system care about cancer? The answer may be simpler than what has been conjectured in the past: the neoplastic process deviates sufficiently from normal tissue physiology to slowly align its phenotype to that of pathogen-infected cells. Simply put, cancer cells look infected to the immune system. Epigenetic alterations germane to cancer cell biology lead to aberrant production of nucleic acids and peptides recapitulating those produced by pathogen-infected cells. This results in two phenomena: (a) production of double stranded nucleic acids that trigger cancer cell intracellular sensors that consequently activate innate immunity; and (b) aberrant production of peptides from genomic regions silenced in normal cells or cancer-specific alteration of cellular processes. The former phenomenon is referred to as “viral mimicry” while the latter is referred to as “dark matter”. The symbiotic interplay between the two phenomena and their causality is the subject of this review.

References

1.
Wang, E.; Worschech, A.; Marincola, F.M. The immunologic constant of rejection. Trends Immunol. 2008, 29, 256–262.
2.
Galon, J.; Angell, H.K.; Bedognetti, D.; et al. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 2013, 39, 11–26.
3.
Wang, E.; Miller, L.D.; Ohnmacht, G.A.; et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002, 62, 3581–3586.
4.
Pages, F.; Mlecnik, B.; Marliot, F.; et al. International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet 2018, 391, 2128–2139.
5.
Mantovani, A.; Romero, P.; Palucka, A.K.; et al. Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet 2008, 371, 771–783.
6.
Kather, J.N.; Suarez-Carmona, M.; Charoentong, P.; et al. Topography of cancer-associated immune cells in human solid tumors. eLife 2018, 7, e36967.
7.
Galon, J.; Lugli, A.; Bifulco, C.; et al. World-Wide Immunoscore Task Force: Meeting report from the “Melanoma Bridge”, Napoli, November 30th-December 3rd, 2016. J. Transl. Med. 2017, 15, 212.
8.
Galon, J.; Fox, B.A.; Bifulco, C.B.; et al. Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015. J. Transl. Med. 2016, 14, 273.
9.
Galon, J.; Pages, F.; Marincola, F.M.; et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 2012, 10, 1.
10.
Pai, S.I.; Cesano, A.; Marincola, F.M. The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treat. Res. 2020, 180, 173–195.
11.
Cesano, A.; Augustin, R.; Barrea, L.; et al. Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: A Society for Immunotherapy of Cancer (SITC) review. J. Immunother. Cancer 2025, 13, e008876.
12.
Sayaman, R.W.; Saad, M.; Thorsson, V.; et al. Germline genetic contribution to the immune landscape of cancer. Immunity 2021, 54, 367–386.e8.
13.
Sayaman, R.W.; Saad, M.; Heimann, C.; et al. Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors. STAR Protoc. 2022, 3, 101809.
14.
Smith, M.; Dai, A.; Ghilardi, G.; et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 2022, 28, 713–723.
15.
Roelands, J.; Kuppen, P.J.K.; Ahmed, E.I.; et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat. Med. 2023, 29, 1273–1286.
16.
Roelands, J.; Hendrickx, W.; Zoppoli, G.; et al. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. J. Immunother. Cancer 2020, 8, e000617.
17.
Hendrickx, W.; Simeone, I.; Anjum, S.; et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology 2017, 6, e1253654.
18.
Miller, L.D.; Chou, J.A.; Black, M.A.; et al. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol. Res. 2016, 4, 600–610.
19.
Hara, T.; Subramanian, M. Rewriting the Fate of Cancer: Epigenetic and Epitranscriptomic Regulators in the Metastatic Cascade. Biomolecules 2025, 15, 1573.
20.
Vatapalli, R.; Rossi, A.P.; Chan, H.M.; Zhang, J. Cancer epigenetic therapy: Recent advances, challenges, and emerging opportunities. Epigenomics 2025, 17, 59–74.
21.
Chen, R.; Ishak, C.A.; De Carvalho, D.D. Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. Cancer Discov. 2021, 11, 2707–2725.
22.
Hu, J.; Ascierto, P.; Cesano, A.; et al. Shifting the paradigm: Engaging multicellular networks for cancer therapy. J. Transl. Med. 2024, 22, 270.
23.
Curtsinger, J.M.; Mescher, M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 2010, 22, 333–340.
24.
Shin, E.C.; Sung, P.S.; Park, S.H. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat. Rev. Immunol. 2016, 16, 509–523.
25.
Nagel, R.; Pataskar, A.; Champagne, J.; Agami, R. Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. Cancer Res. 2022, 82, 3637–3649.
26.
Champagne, J.; Nielsen, M.M.; Feng, X.; et al. Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity 2025, 58, 247–262.e9.
27.
Mariuzza, R.A.; Wu, D.; Pierce, B.G. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity. Front. Immunol. 2023, 14, 1303304.
28.
Sun, S.; Liu, L.; Zhang, J.; et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: Advances, mechanisms, and perspectives. J. Hematol. Oncol. 2025, 18, 84.
29.
Roelands, J.; Kuppen, P.J.K.; Vermeulen, L.; et al. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int. J. Mol. Sci. 2017, 18, 2229.
30.
Weber, J.S.; Carlino, M.S.; Khattak, A.; et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet 2024, 403, 632–644.
31.
McGrail, D.J.; Pilié, P.G.; Rashid, N.U.; et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 2021, 32, 661–672.
32.
Katsikis, P.D.; Ishii, K.J.; Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 2024, 24, 213–227.
33.
Fox, B.A.; Urba, W.J.; Jensen, S.M.; et al. Cancer’s Dark Matter: Lighting the Abyss Unveils Universe of New Therapies. Clin. Cancer Res. 2023, 29, 2173–2175.
34.
Lozano-Rabella, M.; Garcia-Garijo, A.; Palomero, J.; et al. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clin. Cancer Res. 2023, 29, 2250–2265.
35.
Kapranov, P.; St Laurent, G.; Raz, T.; et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is ’dark matter’ un-annotated RNA. BMC Biol. 2010, 8, 149.
36.
Ge, A.; Chan, C.; Yang, X. Exploring the Dark Matter of Human Proteome: The Emerging Role of Non-Canonical Open Reading Frame (ncORF) in Cancer Diagnosis, Biology, and Therapy. Cancers 2024, 16, 2660.
37.
Nelson, B.; Faquin, W. Cancer-aiding elements begin illuminating the genome’s “dark matter”: Within what was once deemed useless junk, virus-like retrotransposons, long noncoding RNAs, and other exotic molecules have emerged as beacons for cancer researchers. Cancer Cytopathol. 2024, 132, 671–672.
38.
De Rosis, S.; Monaco, G.; Hu, J.; et al. The dark matter in cancer immunology: Beyond the visible- unveiling multiomics pathways to breakthrough therapies. J. Transl. Med. 2025, 23, 808.
39.
Zhang, Q.; Yang, H.; Wang, C.; et al. Micropeptides in the oncological dark matter: Decoding their roles in tumor progression and therapy resistance. J. Transl. Med. 2025, 23, 1351.
40.
Rwandamuriye, F.X.; Redwood, A.J.; Creaney, J.; et al. Hidden Targets in Cancer Immunotherapy: The Potential of “Dark Matter” Neoantigens. Vaccines 2026, 14, 104.
41.
Lander, E.S.; Linton, L.M.; Birren, B.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921.
42.
Chong, C.; Müller, M.; Pak, H.; et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 2020, 11, 1293.
43.
Kraemer, A.I.; Chong, C.; Huber, F.; et al. The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nat. Cancer 2023, 4, 608–628.
44.
Huber, F.; Arnaud, M.; Stevenson, B.J.; et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat. Biotechnol. 2025, 43, 1360–1372.
45.
Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015, 162, 974–986.
46.
Roulois, D.; Loo Yau, H.; Singhania, R.; et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 2015, 162, 961–973.
47.
Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301, 89–92.
48.
Weber, J.; Salgaller, M.; Samid, D.; et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 1994, 54, 1766–1771.
49.
Hosseini, A.; Lindholm, H.T.; Chen, R.; et al. Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell Rep. 2024, 43, 113684.
50.
Lindholm, H.T.; Chen, R.; De Carvalho, D.D. Endogenous retroelements as alarms for disruptions to cellular homeostasis. Trends Cancer 2023, 9, 55–68.
51.
de Koning, A.P.; Gu, W.; Castoe, T.A.; et al. Repetitive elements may comprise over two-thirds of the human genome. PLoS Genet. 2011, 7, e1002384.
52.
Zadran, B.; Sudhindar, P.D.; Wainwright, D.; et al. Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: The role of cytoplasmic PIN1 upregulation. Br. J. Cancer 2023, 128, 1236–1248.
53.
Lee, M., Jr.; Ahmad, S.F.; Xu, J. Regulation and function of transposable elements in cancer genomes. Cell. Mol. Life Sci. 2024, 81, 157.
54.
Garcia-Montojo, M.; Doucet-O’Hare, T.; Henderson, L.; et al. Human endogenous retrovirus-K (HML-2): A comprehensive review. Crit. Rev. Microbiol. 2018, 44, 715–738.
55.
Beck, C.R.; Garcia-Perez, J.L.; Badge, R.M.; et al. LINE-1 elements in structural variation and disease. Annu. Rev. Genom. Hum. Genet. 2011, 12, 187–215.
56.
Deininger, P. Alu elements: Know the SINEs. Genome Biol. 2011, 12, 236.
57.
Burns, K.H. Transposable elements in cancer. Nat. Rev. Cancer 2017, 17, 415–424.
58.
Rodić, N.; Sharma, R.; Sharma, R.; et al. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am. J. Pathol. 2014, 184, 1280–1286.
59.
Roulois, D.; Yau, H.L.; De Carvalho, D.D. Pharmacological DNA demethylation: Implications for cancer immunotherapy. OncoImmunology 2016, 5, e1090077.
60.
Miladi, M.; Raden, M.; Diederichs, S.; et al. MutaRNA: Analysis and visualization of mutation-induced changes in RNA structure. Nucleic Acids Res. 2020, 48, W287–W291.
61.
Mehdipour, P.; Marhon, S.A.; Ettayebi, I.; et al. Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. Nature 2020, 588, 169–173.
62.
Cottrell, K.A.; Ryu, S.; Pierce, J.R.; et al. Induction of Viral Mimicry Upon Loss of DHX9 and ADAR1 in Breast Cancer Cells. Cancer Res. Commun. 2024, 4, 986–1003.
63.
Roers, A.; Hiller, B.; Hornung, V. Recognition of Endogenous Nucleic Acids by the Innate Immune System. Immunity 2016, 44, 739–754.
64.
Nesci, S.; Marchi, S.; Hu, J.; et al. Inflammatory mitochondrial signalling and viral mimicry in cancer. J. Transl. Med. 2025, 23, 982.
65.
Yoneyama, M.; Kikuchi, M.; Matsumoto, K.; et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005, 175, 2851–2858.
66.
Hou, G.; Beatty, W.; Ren, L.; et al. SAMD9 senses cytosolic double-stranded nucleic acids in epithelial and mesenchymal cells to induce antiviral immunity. Nat. Commun. 2025, 16, 3756.
67.
Wang, J.; Gao, J.; Huang, C.; et al. Roles of AIM2 Gene and AIM2 Inflammasome in the Pathogenesis and Treatment of Psoriasis. Front. Genet. 2022, 13, 929162.
68.
Volkman, H.E.; Cambier, S.; Gray, E.E.; et al. Tight nuclear tethering of cGAS is essential for preventing autoreactivity. eLife 2019, 8, e47491.
69.
Ishak, C.A.; Classon, M.; De Carvalho, D.D. Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer. Trends Cancer 2018, 4, 583–597.
70.
Jiang, Q.X. Structural Variability in the RLR-MAVS Pathway and Sensitive Detection of Viral RNAs. Med. Chem. 2019, 15, 443–458.
71.
Rehwinkel, J.; Gack, M.U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 2020, 20, 537–551.
72.
Tunbak, H.; Enriquez-Gasca, R.; Tie, C.H.C.; et al. The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s. Nat. Commun. 2020, 11, 5387.
73.
Thawani, A.; Ariza, A.J.F.; Nogales, E.; et al. Template and target-site recognition by human LINE-1 in retrotransposition. Nature 2024, 626, 186–193.
74.
McWhirter, S.M.; Tenoever, B.R.; Maniatis, T. Connecting mitochondria and innate immunity. Cell 2005, 122, 645–647.
75.
Seth, R.B.; Sun, L.; Ea, C.K.; et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122, 669–682.
76.
Xu, L.G.; Wang, Y.Y.; Han, K.J.; et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005, 19, 727–740.
77.
Wu, J.; Chen, Z.J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 2014, 32, 461–488.
78.
Li, S.; Wang, L.; Berman, M.; et al. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 2011, 35, 426–440.
79.
Barnett, K.C.; Coronas-Serna, J.M.; Zhou, W.; et al. Phosphoinositide Interactions Position cGAS at the Plasma Membrane to Ensure Efficient Distinction Between Self- and Viral DNA. Cell 2019, 176, 1432–1446.e11.
80.
Hopfner, K.P.; Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 2020, 21, 501–521.
81.
Balka, K.R.; De Nardo, D. Molecular and spatial mechanisms governing STING signalling. FEBS J. 2021, 288, 5504–5529.
82.
An, C.; Li, Z.; Chen, Y.; et al. The cGAS-STING pathway in cardiovascular diseases: From basic research to clinical perspectives. Cell Biosci. 2024, 14, 58.
83.
Sun, L.; Wu, J.; Du, F.; et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339, 786–791.
84.
Shang, G.; Zhang, C.; Chen, Z.J.; et al. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP. Nature 2019, 567, 389–393.
85.
Huang, Y.H.; Liu, X.Y.; Du, X.X.; et al. The structural basis for the sensing and binding of cyclic di-GMP by STING. Nat. Struct. Mol. Biol. 2012, 19, 728–730.
86.
Ishikawa, H.; Barber, G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455, 674–678.
87.
Abe, T.; Barber, G.N. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J. Virol. 2014, 88, 5328–5341.
88.
McArthur, K.; Whitehead, L.W.; Heddleston, J.M.; et al. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science 2018, 359, eaao6047.
89.
Kim, J.; Kim, H.S.; Chung, J.H. Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp. Mol. Med. 2023, 55, 510–519.
90.
Chen, Q.; Li, Y.; Liu, Y.; et al. Exosomal Non-coding RNAs-Mediated Crosstalk in the Tumor Microenvironment. Front. Cell Dev. Biol. 2021, 9, 646864.
91.
West, A.P.; Khoury-Hanold, W.; Staron, M.; et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 2015, 520, 553–557.
92.
Gomez, S.; Cox, O.L.; Walker, R.R., 3rd; et al. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J. Immunother. Cancer 2022, 10, e004974.
93.
Prinz, F.; Jonas, K.; Balihodzic, A.; et al. MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response. RNA Biol. 2022, 19, 1305–1315.
94.
Naruse, T.; Ohta, K.; Kato, H.; et al. Immune response to cytosolic DNA via intercellular receptor modulation in oral keratinocytes and fibroblasts. Oral Dis. 2022, 28, 150–163.
95.
Bauernfried, S.; Scherr, M.J.; Pichlmair, A.; et al. Human NLRP1 is a sensor for double-stranded RNA. Science 2021, 371, eabd0811.
96.
Tan, X.; Sun, L.; Chen, J.; et al. Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids. Annu. Rev. Microbiol. 2018, 72, 447–478.
97.
Angelova, M.; Mlecnik, B.; Vasaturo, A.; et al. Evolution of Metastases in Space and Time under Immune Selection. Cell 2018, 175, 751–765.e16.
98.
Ramsoomair, C.K.; Ceccarelli, M.; Heiss, J.D.; et al. The epitranscriptome of high-grade gliomas: A promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses. J. Transl. Med. 2023, 21, 893.
99.
Schneider, W.M.; Chevillotte, M.D.; Rice, C.M. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 2014, 32, 513–545.
100.
Heim, M.H.; Kerr, I.M.; Stark, G.R.; et al. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995, 267, 1347–1349.
101.
Fu, X.Y.; Kessler, D.S.; Veals, S.A.; et al. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 1990, 87, 8555–8559.
102.
Song, N.; Cui, K.; Zeng, L.; et al. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer. Eur. J. Pharmacol. 2024, 967, 176357.
103.
Liu, X.; Ma, Q.; Jia, Z.; et al. The multifaceted roles of ISG15 in cancer: Conjugated and free forms. Biochim. Biophys. Acta Rev. Cancer 2025, 1880, 189473.
104.
Martínez-Riaño, A.; Mosteo, L.; Molero-Glez, P.; et al. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy. Clin. Cancer Res. 2024, 30, 3355–3357.
105.
Park, B.S.; Lee, J.-O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 2013, 45, e66.
106.
Hemmi, H.; Kaisho, T.; Takeuchi, O.; et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway. Nat. Immunol. 2002, 3, 196–200.
107.
Cheng, Y.; Borcherding, N.; Ogunsakin, A.; et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Sci. Rep. 2021, 11, 1535.
108.
Hemmi, H.; Takeuchi, O.; Kawai, T.; et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745.
109.
Zhao, Z.; Ma, Z.; Wang, B.; et al. Mn2+ Directly Activates cGAS and Structural Analysis Suggests Mn2+ Induces a Noncanonical Catalytic Synthesis of 2′3′-cGAMP. Cell Rep. 2020, 32, 108053.
110.
Zhang, X.; Shi, H.; Wu, J.; et al. Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING. Mol. Cell 2013, 51, 226–235.
111.
Nelson, T.S.; Ma, Z. STING agonists as antiviral agents. FEBS Lett. 2025, https://doi.org/10.1002/1873-3468.70251.
112.
Huang, W.; Zhu, Q.; Shi, Z.; et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 2024, 10, 143.
113.
Wu, Q.; Nie, D.Y.; Ba-Alawi, W.; et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat. Chem. Biol. 2022, 18, 821–830.
114.
Diederichs, S.; Bartsch, L.; Berkmann, J.C.; et al. The dark matter of the cancer genome: Aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol. Med. 2016, 8, 442–457.
115.
Sriram, A.; Bohlen, J.; Teleman, A.A. Translation acrobatics: How cancer cells exploit alternate modes of translational initiation. EMBO Rep. 2018, 19, e45947.
116.
Wright, B.W.; Yi, Z.; Weissman, J.S.; et al. The dark proteome: Translation from noncanonical open reading frames. Trends Cell Biol. 2022, 32, 243–258.
117.
Li, L.J.; Leng, R.X.; Fan, Y.G.; et al. Translation of noncoding RNAs: Focus on lncRNAs, pri-miRNAs, and circRNAs. Exp. Cell Res. 2017, 361, 1–8.
118.
Dinger, M.E.; Pang, K.C.; Mercer, T.R.; et al. Differentiating protein-coding and noncoding RNA: Challenges and ambiguities. PLoS Comput. Biol. 2008, 4, e1000176.
119.
Laumont, C.M.; Vincent, K.; Hesnard, L.; et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 2018, 10, eaau5516.
120.
Xie, N.; Shen, G.; Gao, W.; et al. Neoantigens: Promising targets for cancer therapy. Signal Transduct. Target. Ther. 2023, 8, 9.
121.
Zhao, X.; Wei, L.; Zhang, X. Computational methods and data resources for predicting tumor neoantigens. Brief. Bioinform. 2025, 26, bbaf302.
122.
Fabris, L.; Calin, G.A. Understanding the Genomic Ultraconservations: T-UCRs and Cancer. Int. Rev. Cell Mol. Biol. 2017, 333, 159–172.
123.
Luksza, M.; Sethna, Z.M.; Rojas, L.A.; et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 2022, 606, 389–395.
124.
Cherkasova, E.; Scrivani, C.; Doh, S.; et al. Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cancer Res. 2016, 76, 2177–2185.
125.
Rycaj, K.; Plummer, J.B.; Yin, B.; et al. Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin. Cancer Res. 2015, 21, 471–483.
126.
Garde, C.; Pavlidis, M.A.; Garces, P.; et al. Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines. npj Vaccines 2025, 10, 54.
127.
Bozgeyik, I. The dark matter of the human genome and its role in human cancers. Gene 2022, 811, 146084.
128.
Marini, A.; Lena, A.M.; Panatta, E.; et al. Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget 2017, 8, 35669–35680.
129.
Gao, S.S.; Zhang, Z.K.; Wang, X.B.; et al. Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives. World J. Gastroenterol. 2022, 28, 2900–2909.
130.
Kottorou, A.E.; Antonacopoulou, A.G.; Dimitrakopoulos, F.D.; et al. Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas. Oncotarget 2018, 9, 21411–21428.
131.
Gibert, M.K., Jr.; Sarkar, A.; Chagari, B.; et al. Transcribed Ultraconserved Regions in Cancer. Cells 2022, 11, 1684.
132.
Edwards, J.K.; Pasqualini, R.; Arap, W.; et al. MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases. J. Cardiovasc. Transl. Res. 2010, 3, 271–279.
133.
Kore, H.; Datta, K.K.; Nagaraj, S.H.; et al. Protein-coding potential of non-canonical open reading frames in human transcriptome. Biochem. Biophys. Res. Commun. 2023, 684, 149040.
134.
Zhang, M.; Zhao, K.; Xu, X.; et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat. Commun. 2018, 9, 4475.
135.
Avesson, L.; Barry, G. The emerging role of RNA and DNA editing in cancer. Biochim. Biophys. Acta Rev. Cancer 2014, 1845, 308–316.
136.
Paz-Yaacov, N.; Bazak, L.; Buchumenski, I.; et al. Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. Cell Rep. 2015, 13, 267–276.
137.
Peng, X.; Xu, X.; Wang, Y.; et al. A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell 2018, 33, 817–828.e7.
138.
Zhang, M.; Fritsche, J.; Roszik, J.; et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 2018, 9, 3919.
139.
Fedoriw, A.; Shi, L.; O’Brien, S.; et al. Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses. Cancer Immunol. Res. 2022, 10, 420–436.
140.
Champagne, J.; Mordente, K.; Nagel, R.; et al. Slippy-Sloppy translation: A tale of programmed and induced-ribosomal frameshifting. Trends Genet. 2022, 38, 1123–1133.
141.
Pataskar, A.; Champagne, J.; Nagel, R.; et al. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature 2022, 603, 721–727.
142.
Kahles, A.; Lehmann, K.V.; Toussaint, N.C.; et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell 2018, 34, 211–224.e6.
143.
Wang, B.D.; Lee, N.H. Aberrant RNA Splicing in Cancer and Drug Resistance. Cancers 2018, 10, 458.
144.
Bigot, J.; Lalanne, A.I.; Lucibello, F.; et al. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021, 11, 1938–1951.
145.
Zarling, A.L.; Polefrone, J.M.; Evans, A.M.; et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 2006, 103, 14889–14894.
146.
Berkers, C.R.; de Jong, A.; Schuurman, K.G.; et al. Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. J. Immunol. 2015, 195, 4085–4095.
147.
Pockaj, B.A.; Sherry, R.M.; Wei, J.P.; et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994, 73, 1731–1737.
148.
Blass, E.; Keskin, D.B.; Tu, C.R.; et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 2025, 188, 5125–5141.e27.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us